NEWS RELEASE - For Immediate Release

Celsense, Inc. Launches a New Dual-mode Imaging Agent Enabling Inflammation Detection by MRI and Fluorescence

August 20, 2011 - Pittsburgh, Pennsylvania

Celsense, Inc. announced today the launch of a new dual-mode version of its inflammation imaging reagent, V- Sense

V-Sense is an injectable perfluorocarbon magnetic resonance imaging (MRI) tracer agent that labels leukocytes in situ, enabling the non-invasive visualization and quantification of localized inflammation. The newly launched dual-mode agent V-Sense DM Green provides investigators with a tool to accelerate preclinical validation studies. V-Sense DM Green contains a bright fluorescent dye bound to the MRI-active perfluorocarbon. Post-MRI, biopsied or necropsied tissues can be further analyzed using fluorescence microscopy or flow cytometry methods. In vivo fluorescence imaging is also possible using V-Sense DM Green. This true dual-mode agent is expected to enhance the adoption rate of the V-Sense platform in preclinical studies. 

About V- Sense
V-Sense is a proprietary perfluorocarbon emulsion. V-Sense is safe for direct intravenous injection for preclinical studies. Following injection, the emulsion droplets are internalized by circulating monocytes and macrophage. These labeled cells accumulate at inflammatory sites in vivo and are detected by fluorine-19 (19F) MRI, or alternatively, by NMR in excised tissue. The key advantage of using 19F detection is that there is no background signal from the host’s tissues. Quantification of the 19F signal yields a fast, accurate marker of the degree of inflammation present that is directly proportional to the macrophage/monocyte tissue burden.  V-Sense can be used to detect a wide range of lesions and diseases where inflammation is a hallmark, such as cancer and infections, and autoimmune diseases. V-Sense is also used for pharmacological safety profiling to detect ‘off target’ inflammatory side effects in preclinical drug screens.

About Celsense, Inc.
Celsense, Inc. offers products that enable the non-invasive imaging of inflammation and transplanted cells using MRI. The mission of the company is to be the standard for cellular imaging in human health.

Celsense, Inc. markets three reagent families for MRI of cells for discovery, pre-clinical research and translational medicine.  The company also offers the Voxel Tracker software for visualizing and quantifying cells in MRI data sets. Customers include leading pharmaceutical and biotechnology companies and biomedical research centers worldwide. 

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870